SARS-CoV-2无标记替代病毒中和试验及COVID-19患者抗体特征纵向研究
在无标记免疫分析平台上建立替代病毒中和试验(LF-sVNT),检测113例COVID-19患者246份血清样本的中和抗体滴度(IC50)、IgG浓度和IgG亲和力指数,并进行纵向观察。结果显示IgG浓度和中和抗体滴度在症状出现40天后先升、平台期、部分病例后期渐降;IgG亲和力指数先升后平台、不下降。本研究首次提供症状出现后200天以上的纵向中和抗体滴度,中和活性下降可归因于抗体数量减少而非质量下降。
要点
- LF-sVNT通过检测RBD与ACE2结合阻断能力反映中和抗体水平。
- IgG浓度和中和抗体滴度在症状后40天呈现升、平台、部分渐降。
- IgG亲和力指数先升后平台且不下降,中和活性下降源于抗体量减少。
核心结论
- LF-sVNT可用于评估COVID-19中和抗体存在,中和活性下降主要因抗体数量减少而非亲和力下降。
研究设计与样本
- 在无标记免疫分析平台建立LF-sVNT,检测113例COVID-19患者共246份血清样本的中和抗体滴度(IC50)、IgG浓度和IgG亲和力指数,并进行纵向观察。
主要发现
- 个体间IgG浓度和中和抗体滴度动力学存在差异,但症状出现40天后呈初始上升、平台、部分病例后期渐降。
- IgG亲和力指数先升后平台且不下降,研究首次提供症状出现后200天以上的纵向中和抗体滴度。
关键数值与推荐
- LF-sVNT以50%抑制浓度(IC50)表示中和抗体滴度。
- IgG亲和力指数在感染后8个月维持平台且不下降。
临床怎么用
- LF-sVNT可用于研究和临床实验室评估COVID-19中和抗体存在。
- 解读中和活性下降时应考虑抗体数量减少而非质量下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Methods designed to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) humoral response include virus neutralization tests to determine antibody neutralization activity. For ease of use and universal applicability, surrogate virus neutralization tests (sVNTs) based on antibody-mediated blockage of molecular interactions have been proposed. A surrogate virus neutralization test was established on a label-free immunoassay platform (LF-sVNT). The LF-sVNT analyzes the binding ability of SARS-CoV-2 spike protein receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2) after neutralizing RBD with antibodies in serum. The LF-sVNT neutralizing antibody titers (50% inhibitory concentration [IC50]) were determined from serum samples (n = 246) from coronavirus disease 2019 (COVID-19) patients (n = 113), as well as the IgG concentrations and the IgG avidity indices. Although there was variability in the kinetics of the IgG concentrations and neutralizing antibody titers between individuals, there was an initial rise, plateau, and then in some cases a gradual decline at later time points after 40 days after symptom onset. The IgG avidity indices, in the same cases, plateaued after an initial rise and did not show a decline. The LF-sVNT can be a valuable tool in research and clinical laboratories for the assessment of the presence of neutralizing antibodies to COVID-19. This study is the first to provide longitudinal neutralizing antibody titers beyond 200 days post-symptom onset. Despite the decline of IgG concentration and neutralizing antibody titer, IgG avidity index increases, reaches a plateau, and then remains constant up to 8 months postinfection. The decline of antibody neutralization activity can be attributed to the reduction in antibody quantity rather than the deterioration of antibody quality, as measured by antibody avidity.
引用
- Luo YR, Yun C, Chakraborty I, et al. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. J Clin Microbiol. 2021. PMID: 33827900. doi:10.1128/JCM.00193-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。